Publication date: Mar 15, 2019
This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration.Funding: Merck Serono Middle East FZ LTD.
Alroughani, R., Inshasi, J.S., Deleu, D., Al-Hashel, J., Shakra, M., Elalamy, O.R., Shatila, A.O., Al-Asmi, A., Sharoqi, Al, Canibano, B.G., and Boshra, A. An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. 17524. 2019 Neurol Ther.
- Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
- Angiopoietin-like proteins in multiple sclerosis.
- EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019
- Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
- New Warning for the Multiple Sclerosis Drug Alemtuzumab.